| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jian Lu | Q81779949 |
| Ling Ni | Q90435678 | ||
| P2860 | cites work | IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression | Q87848206 |
| Interferon-gamma induces autophagy-associated apoptosis through induction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells | Q88091546 | ||
| Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab | Q88537041 | ||
| Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment | Q88796921 | ||
| Interleukin 33 signaling restrains sporadic colon cancer in an interferon-gamma-dependent manner. | Q49791560 | ||
| Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. | Q49912481 | ||
| In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. | Q50882019 | ||
| Cellular teamwork in antibacterial innate immunity. | Q50972079 | ||
| Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. | Q50974735 | ||
| IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. | Q52727974 | ||
| Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. | Q54278902 | ||
| PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer | Q56898302 | ||
| PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations | Q28075712 | ||
| The roles of IFN gamma in protection against tumor development and cancer immunoediting | Q28207895 | ||
| Interferons, immunity and cancer immunoediting | Q28270336 | ||
| Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
| Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells | Q33702231 | ||
| MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress | Q33713506 | ||
| IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1. | Q34076238 | ||
| The origins of cancer robustness and evolvability. | Q34143477 | ||
| VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth | Q34439393 | ||
| Comparison of the regulation of β-catenin signaling by type I, type II and type III interferons in hepatocellular carcinoma cells | Q34442738 | ||
| RelA-Induced Interferon Response Negatively Regulates Proliferation | Q35804406 | ||
| Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. | Q36016640 | ||
| Inflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines | Q36085880 | ||
| Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 | ||
| PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines | Q36334073 | ||
| Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells | Q36521314 | ||
| Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial | Q36621312 | ||
| Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. | Q37046734 | ||
| Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues | Q37115223 | ||
| Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression | Q37297734 | ||
| Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. | Q37687020 | ||
| IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment | Q38699928 | ||
| The untold story of IFN-γ in cancer biology. | Q38922272 | ||
| Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages | Q38973749 | ||
| Interferon-γ produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells | Q39076405 | ||
| Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity | Q39234961 | ||
| IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor | Q41228057 | ||
| Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. | Q41493082 | ||
| Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression | Q41590802 | ||
| Twist1 regulates Ifng expression in Th1 cells by interfering with Runx3 function. | Q41954129 | ||
| M2-polarised macrophages in infantile haemangiomas: correlation with promoted angiogenesis | Q44492571 | ||
| Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells | Q47123300 | ||
| Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines | Q47783217 | ||
| Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. | Q47799445 | ||
| PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. | Q48184221 | ||
| Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-γ and induces NK cell-dependent lymphoma control without other immunotherapies. | Q48240289 | ||
| Interferon-γ and Colorectal Cancer: an up-to date | Q49199768 | ||
| Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. | Q49501422 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P921 | main subject | neoplasm | Q1216998 |
| immunotherapy | Q1427096 | ||
| immunologic factor | Q50349184 | ||
| P304 | page(s) | 4509-4516 | |
| P577 | publication date | 2018-07-23 | |
| 2018-09-01 | |||
| P1433 | published in | Cancer Medicine | Q27724564 |
| P1476 | title | Interferon gamma in cancer immunotherapy | |
| P478 | volume | 7 |
| Q100737000 | Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients |
| Q98177744 | Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective |
| Q89576428 | Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma |
| Q92608513 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors |
| Q103756621 | IFNgamma-inducible CXCL10/CXCR3 axis alters the sensitivity of HEp-2 cells to ionizing radiation |
| Q99622572 | Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma |
| Q91711786 | NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes |
| Q64078881 | Novel predication of protein biomarkers in interferon-gamma-stimulated breast cancer cells |
| Q64117476 | PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ |
| Q98776112 | Searching for the real function of mTOR signaling in the regulation of PD-L1 expression |
| Q91898387 | Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy |
| Q97644684 | The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration |
| Q96816703 | The interaction between ferroptosis and lipid metabolism in cancer |
| Q92669055 | Transcriptome meta-analysis reveals differences of immune profile between eutopic endometrium from stage I-II and III-IV endometriosis independently of hormonal milieu |
| Q101136383 | Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images |
Search more.